Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT06300320

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2025-02-11

52

Participants Needed

12

Research Sites

99 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease

CONDITIONS

Official Title

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntary and signed informed consent, good compliance
  • Aged 18 to 70 years old
  • Karnofsky Performance Scale (KPS) 60 points or higher
  • Life expectancy of at least 6 months
  • Received allogeneic hematopoietic stem cell transplantation
  • Diagnosed with moderate-to-severe chronic graft-versus-host disease (cGVHD)
  • Received systemic therapies for cGVHD
  • Stable dose of glucocorticoids or other immunosuppressant therapy within 2 weeks prior to screening
  • Absolute Neutrophil Count (ANC) of at least 1.0 x 10^9/L
  • Platelet count (PLT) of at least 30 x 10^9/L
  • Hemoglobin level of at least 80 g/L
  • No obvious abnormalities in liver, kidney, or coagulation function
  • Men and women of childbearing potential agree to use contraception during the study and for 6 months after
Not Eligible

You will not qualify if you...

  • Current or past other malignancies within 3 years prior to first administration
  • Known or suspected active acute graft-versus-host disease (aGVHD)
  • Infection requiring treatment within 7 days prior to randomization
  • Failed allogeneic hematopoietic stem cell transplantation within 6 months or had 2 prior allogeneic transplants
  • Use of JAK inhibitors, BTK inhibitors, or chemotherapy within 2 weeks prior to randomization
  • Conditions affecting oral medication intake (e.g., inability to swallow, intestinal obstruction)
  • History of psychotropic drug abuse or mental disorder preventing abstinence
  • Severe or uncontrolled serious illnesses including uncontrolled hypertension, heart disease, hepatitis, or epilepsy requiring treatment
  • Allergy to the study drug or its components
  • Participation in other clinical trials or major surgery within 4 weeks prior to first dose
  • Judged unsuitable for enrollment by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

Anhui Provincial Hospital

Hefei, Anhui, China, 230001

Not Yet Recruiting

2

The 940th hospital of joint logistics support force of Chinese people's liberation army

Lanzhou, Gansu, China, 730050

Not Yet Recruiting

3

Guangzhou First People's Hospital

Guangzhou, Guangdong, China, 510180

Not Yet Recruiting

4

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China, 530021

Not Yet Recruiting

5

The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, China, 050000

Not Yet Recruiting

6

Xiangyang Central Hospital

Xiangyang, Hubei, China, 441021

Not Yet Recruiting

7

Tai'an Central Hospital

Taian, Shangdong, China

Not Yet Recruiting

8

Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China, 200025

Not Yet Recruiting

9

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shannxi, China, 710299

Not Yet Recruiting

10

Hematology Hospital of the Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, China, 300020

Not Yet Recruiting

11

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

12

The Affiliated People's Hospital of Ningbo University

Ningbo, Zhejiang, China, 315040

Not Yet Recruiting

Loading map...

Research Team

H

He Huang, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here